Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:RARX

Ra Pharmaceuticals (RARX) Stock Price, News & Analysis

Ra Pharmaceuticals logo

About Ra Pharmaceuticals Stock (NASDAQ:RARX)

Key Stats

Today's Range
$47.99
$47.99
50-Day Range
$47.99
$48.00
52-Week Range
$19.64
$48.02
Volume
30,200 shs
Average Volume
1.16 million shs
Market Capitalization
$2.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Receive RARX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RARX Stock News Headlines

RA: Discount Continues To Leave Some Opportunity
Elon Musk has put himself in their crosshairs
Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.
RARX_old Historical Data
See More Headlines

RARX Stock Analysis - Frequently Asked Questions

Ra Pharmaceuticals Inc (NASDAQ:RARX) posted its quarterly earnings results on Thursday, February, 27th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by $0.16.

Ra Pharmaceuticals (RARX) raised $75 million in an initial public offering on Wednesday, October 26th 2016. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ra Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Gilead Sciences (GILD), Verastem (VSTM), Amarin (AMRN), Bausch Health Companies (BHC) and Galmed Pharmaceuticals (GLMD).

Company Calendar

Last Earnings
2/27/2020
Today
11/14/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RARX
Fax
N/A
Employees
72
Year Founded
N/A

Profitability

Net Income
$-102,690,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3 million
Book Value
$5.56 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.27 billion
Optionable
Optionable
Beta
1.05
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:RARX) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners